Evaxion Biotech A/S reports results for the quarter ended in September - Earnings Summary

Evaxion A/S

19/12/2023 22:03

* Evaxion Biotech A/S  EVAX.OQ  reported a quarterly
adjusted loss
of 21 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -24 cents.  The mean expectation of two analysts
for the quarter was for a loss of 19 cents per share. Wall
Street expected results to range from -20 cents to -19 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Evaxion Biotech A/S's reported EPS for the quarter was a
loss
of 21 cents​.
    * The company reported a quarterly loss of $5.68 million.
    * Evaxion Biotech A/S shares had fallen by 23.0% this
quarter and
lost 63.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Evaxion Biotech
A/S is $7.00 
This summary was machine generated from LSEG data December 19 at
10:03 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.19          -0.21          Missed
 Jun. 30 2023      -0.21          -0.21          Met
 Mar. 31 2023      -0.24          -0.24          Met
 Dec. 31 2022      -0.26          -0.29          Missed